Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism.
Maya Chopra, Meriel McEntagart, Jill Clayton-Smith...
https://pubmed.ncbi.nlm.nih.gov/33909992/Actively Recruiting
Led by Boston Children's Hospital · Updated on 2026-02-17
125
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating Chopra-Amiel-Gordon Syndrome CAGS, a rare genetic disorder caused by changes in the ANKRD17 gene. This study aims to understand the range of symptoms, brain changes seen on imaging, and learning difficulties in individuals with confirmed or suspected CAGS. The study also explores the relationship between genetic variations and the clinical features of this condition through detailed assessments and patient data collected over time. Participants include those with confirmed or suspected CAGS based on genetic testing and clinical features, as well as unaffected family members for comparison. The study involves annual visits where medical and family histories, MRI scans, photographs, genetic test results, and questionnaires about behavior and quality of life are collected. Participants may also undergo neurobehavioral assessments, EEGs, and provide blood or skin samples for research purposes related to neuronal cell studies. During the study, researchers will maintain a secure database of all collected information and samples. They aim to generate patient-specific cell lines to study neuronal characteristics and better understand the disorders biology. The primary outcomes include building a registry of molecular and phenotypic data and creating induced pluripotent stem cell lines over 4 to 5 years. The study continues over multiple years with annual evaluations to track changes and gather comprehensive data on CAGS.
CONDITIONS
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
A
Abigail Sveden, MS, CGC
J
Jillian O'Toole, MS, CGC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Boston Children's Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 to 5 years
Participants are observed with annual systematic evaluations of clinical, neuroimaging, and neuronal cellular features to better understand the spectrum and progression of Chopra-Amiel-Gordon Syndrome.
Annual visits for up to 5 years
Duration - Varies by participant
Collection of blood and/or skin samples for research purposes.
1 to 2 visits depending on sample type
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maya Chopra, Meriel McEntagart, Jill Clayton-Smith...
https://pubmed.ncbi.nlm.nih.gov/33909992/Boston Children's Hospital
Lead Sponsor